A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of care in the Treatment of Hospitalized Cancer Patients with Severe COVID-19

Matthew Dallos, Assistant Professor of Medicine at CUMC, Division of Hematology/Oncology

This is a single center, randomized, open-label, phase two trial to evaluate the time-to-improvement in the seven point ordinal scale following treatment with BMS-986253 compared to standard of care in hospitalized cancer patients with COVID-19 respiratory disease.